Securities Class Actions – Page 59 – ClaimsFiler

Case Type: Securities Class Actions

According to the Complaint, Sprint is a communications company offering a comprehensive range of wireless and wireline communications products and services that are designed to meet the needs of individual consumers, businesses, government subscribers and resellers.

According to the Complaint, Bloom Energy designs, manufactures, and sells solid-oxide fuel cell systems for on-site power generation. The fuel cell systems, or Energy Servers, convert fuel into electricity without combustion, providing efficient energy generation with reduced operating costs and lower greenhouse gas emissions.

According to the Complaint, RCI is a holding company that operates live adult entertainment and/or restaurant and bar operations through its subsidiaries. It has two principal reportable segments: Nightclubs and Bombshells.

According to the Complaint, AAC provides inpatient and outpatient substance use treatment services for individuals with drug addiction, alcohol addiction, and co-occurring mental/behavioral health issues in the United States.

According to the Complaint, Dynagas is a publicly traded company limited partnership that owns six tanker ships, designed for the transportation of liquified natural gas ("LNG"). These LNG tanker ships are operated by a Dynagas affiliate and are chartered to large energy companies including Statoil (now known as Equinor), Gazprom, and Yamal, typically for periods of eight to ten years.

According to the Complaint, Intersect is a commercial drug delivery company that purports to develop products for patients with ear, nose, and throat conditions. The Company's PROPEL family of products are used in conjunction with sinus surgery, and the Company's SINUVA sinus implant is used to treat patients who have had surgery yet suffer from recurrent sinus obstruction due to polyps.

According to the Complaint, Nabriva Therapeutics plc is a biopharmaceutical company that purports to develop novel antiinfective agents to treat serious infections. One of the Company's product candidates is CONTEPO, an epoxide antibiotic developed by Zavante Therapeutics ("Zavante"), which the Company acquired in July 2018.

According to the Complaint, Papa Murphy’s is a franchisor and operator of the largest “Take ‘n’ Bake” pizza brand in the United States, selling hand-crafted, fresh pizzas for customers to bake at home.

According to the Complaint, Indivior together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The Company’s product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia.

According to the Complaint, APYX Medical Corporation is a medical technology company that purportedly develops J-Plasma, a plasma-based surgical product for cutting, coagulation and ablation of soft tissue. The Company markets and sells J-Plasma under the brand name Renuvion Cosmetic Technology. The Company claims that it has developed J-Plasma/Renuvion for use in dermal resurfacing procedures. Apyx was formerly known as Bovie Medical Corporation, and its stock traded on the New York Stock Exchange ("NYSE") under the symbol "BVX" until January 1, 2019.

According to the Complaint, Apple is a multinational technology company headquartered in Cupertino, California that designs, develops, and sells consumer electronics, computer software, and online services. The Company's most well-known products include its iconic iPhone smartphones, the iPad tablet computer, the Mac personal computer, the iPod portable media player, the Apple Watch smartwatch, the Apple TV digital media player, and the HomePod smart speaker.

According to the Complaint, Taronis purportedly operates as an energy company that offers technology solutions to create, process, and produce hydrogen-based fuel through the gasification of carb-rich liquids. Taronis formerly operated under the name of MagneGas Applied Technology Solutions, Inc.

According to the Complaint, Amyris purports to be an industrial biotechnology company that manufactures and
sells natural, sustainably-sourced products in health and wellness, clean beauty, and flavor and fragrance markets.

According to the law firm press release, the complaint alleges that the Offering Documents failed to disclose that: (1) a shortage of trucks was negatively impacting U.S. Xpress's dedicated division; (2) (a) certain shipping patterns had been performing differently than expected and, as a result, (b) utilization and driver retention and hiring were being negatively affected, and as a result, (c) U.S. Xpress's dedicated accounts, including one large account, were being negatively impacted; and as a result, (d) U.S. Xpress's OTR division was providing continued support to the dedicated division; (3) (a) U.S. Xpress failed to stay informed regarding two large liability events; and as a result (b) U.S. Xpress's insurance claim expense was understated; and (4) U.S. Xpress's cost per mile for driver wages and independent contractors was exceeding the Company's internal expectations.

We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.

OK